The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) reached all time low today, Nov, 4 and still has $2.16 target or 12.00% below today’s $2.45 share price. This indicates more downside for the $120.17M company. This technical setup was reported by Barchart.com. If the $2.16 PT is reached, the company will be worth $14.42 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock last traded at $2.45 per share. It is down 68.39% since April 4, 2016 and is downtrending. It has underperformed by 69.48% the S&P500.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Wedbush given on Wednesday, August 5. As per Wednesday, November 2, the company rating was maintained by Needham. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Outperform”. As per Wednesday, April 13, the company rating was initiated by Chardan Capital Markets. On Tuesday, June 28 the stock rating was maintained by Chardan Capital Markets with “Buy”. Wells Fargo initiated Regulus Therapeutics Inc (NASDAQ:RGLS) on Friday, December 4 with “Outperform” rating. The firm has “Market Perform” rating by BMO Capital Markets given on Tuesday, June 28. The stock has “Buy” rating given by Needham on Tuesday, June 28. The firm has “Buy” rating given on Tuesday, June 7 by Chardan Capital Markets.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.19, from 1.04 in 2016Q1. The ratio improved, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Blackrock Advsr Ltd Com has 0% invested in the company for 16,099 shares. Commercial Bank Of America Corporation De holds 0% or 5,557 shares in its portfolio. Ladenburg Thalmann Svcs Incorporated accumulated 2,000 shares or 0% of the stock. Deutsche Savings Bank Ag has 104,214 shares for 0% of their US portfolio. The Illinois-based Citadel has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Moreover, State Street Corp has 0% invested in Regulus Therapeutics Inc (NASDAQ:RGLS) for 551,539 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 1,508 shares. Legal General Public Limited Company holds 6,785 shares or 0% of its portfolio. Citigroup Inc holds 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 14,322 shares. Globeflex Lp owns 80,637 shares or 0.06% of their US portfolio. Fmr Ltd Liability Co holds 7.92M shares or 0% of its portfolio. Schroder Mgmt Grp Inc holds 109,987 shares or 0% of its portfolio. The Kentucky-based Teachers Retirement Sys Of The State Of Kentucky has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Morgan Stanley accumulated 28,009 shares or 0% of the stock. Voya Mgmt Limited Liability Com last reported 0% of its portfolio in the stock.
More important recent Regulus Therapeutics Inc (NASDAQ:RGLS) news were published by: Fool.com which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016, also Fool.com published article titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April”, Marketwatch.com published: “Regulus Therapeutics’ stock set to fall after FDA places hepatitis C treatment …” on June 27, 2016. More interesting news about Regulus Therapeutics Inc (NASDAQ:RGLS) was released by: Marketwatch.com and their article: “Regulus Therapeutics stock surges after ‘promising’ Hep C drug trial results” with publication date: February 17, 2016.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.